NCT02570542: Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Active, not recruiting | 2 | 59 | US | leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, BEAM chemotherapy, Autologous Stem Cell Transplantation | Memorial Sloan Kettering Cancer Center, Columbia University, NorthShore University HealthSystem, University of Rochester, Medical College of Wisconsin, University of Nebraska, Sanofi, University Hospitals Seidman Cancer Center | Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL) | 10/25 | 10/25 | | |
NCT01745588: Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 2 | 23 | US | Pomalidomide, stem cell, Dexamethasone, Clarithromycin | Memorial Sloan Kettering Cancer Center, Celgene Corporation, Weill Medical College of Cornell University, North Shore University Hospital, Rutgers Cancer Institute of New Jersey, State University of New York - Upstate Medical University | Multiple Myeloma | 12/25 | 12/25 | | |
